Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

f symptoms and complications including anemia, weakness, fatigue, infection and bleeding. Bone marrow failure results in death from bleeding and infection in the majority of patients, while transformation from MDS to acute myelogenous leukemia (AML) occurs in up to 40 percent of patients. The highest incidence of MDS is in patients over 60 years of age.

According to the Aplastic Anemia and MDS International Foundation, approximately 10,000-30,000 new cases of MDS are diagnosed each year in the United States, although it is difficult to accurately determine the incidence because MDS is not a disease for which the Centers for Disease Control and Prevention (CDC) mandates reporting of cases.

About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company focuses on some of the most promising areas of oncology such as histone deacetylase (HDAC) and kinase inhibitors. The Company's lead product is MGCD0103, an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza and Gemzar(r). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical HDAC programs in non-oncology indications such as fungal infections (clinical candidate MGCD290 in combination with azoles to overcome resistance) and Huntington's disease. The company also has a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical,

Merck and EnVivo Pharmaceuticals. Please visit our website at www.methylgene.com.

About Pharmion

Pharmion is a biophar
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... announced today development of a novel means of ... nucleic acid, RGBP-248, to liver tumors utilizing a ... in development overcomes previous hurdles with gene silencing ... to be delivered throughout the whole body.  By ...
(Date:8/31/2015)... 31, 2015 BioLight ... BLGTY) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, today announced that its ... identified several new genetic markers with high potential ... treated with bisphosphonate drugs and was able to ...
(Date:8/31/2015)... ALBANY, N.Y. , Aug. 31, 2015 /PRNewswire/ ... a.s. today announced a strategic collaboration focused on ... of opium-derived active pharmaceutical ingredients, ("APIs"). The collaboration ... biomass and their expertise in developing and manufacturing ... their ability to tech transfer processes into these ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
... April 20, 2012 West Physics Consulting, the leading ... testing services, announced today that it has entered into ... Mirion Technologies to provide dosimetry services. The ... of services and products to medical and industrial users ...
... 20, 2012 Rapid Fire Marketing (Pink Sheets: ... deal with a California Manufacturer to begin the development of the ... begin early next. Once all specifications are met, the manufacturing facility ... will also file for a patent of the new device once ...
Cached Medicine Technology:West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services 2Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler 2
(Date:8/31/2015)... ... August 31, 2015 , ... American Family ... is enhancing its existing presence in Tennessee with the opening of a new ... company’s second in Knoxville, sixteenth in Tennessee, and 148th in the U.S. overall. ...
(Date:8/31/2015)... ... August 31, 2015 , ... People with hostile personality ... risk for injury, potentially because they are more susceptible to the influence of ... Public Health analysis discovered. , The research, published online in the International ...
(Date:8/31/2015)... Valley, CA (PRWEB) , ... August 31, 2015 , ... ... Ghasri, to the practice. Dr. Pedram Ghasri is a graduate of the University of ... neuroscience and continued his studies at the University of California, Irvine Medical School. As ...
(Date:8/31/2015)... ... August 31, 2015 , ... The German soccer ... management system (CMS) and make website updates quicker and more flexible. The company's ... of the Bundesliga (the German equivalent of the U.S. Soccer Federation) more modern, ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While ... device that could effectively deliver oxygen with a lower risk of failure," explained ... way, I invented the Adam Device." , The Adam Device offers a quick, ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... community cooperation, building on skills and strengths, and getting strangers ... Now, a pilot study of six families living ... infusions of cash could fuel such cooperation and produce overlapping ... migrant workers have assets as well as significant health-care needs, ...
... used multivitamins during and after being treated with post-surgical chemotherapy ... their dying from it, according to researchers at Dana-Farber Cancer ... colon cancer characterized as cancer in the large bowel ... nodes -- the researchers found that while multivitamin use had ...
... Sinai School of Medicine have discovered a major mechanism ... The discovery may help researchers find new therapies to ... associated with morphine use. The findings are published in ... Overcoming tolerance to morphine after chronic administration has ...
... YORK, NY September 7, 2010 Clinical trials ... that will be presented at TCT 2010 will directly ... treated. Breakthroughs in science and medical research, presented exclusively ... minimally invasive and involve shorter recovery times. Among the ...
... HealthDay Reporter , TUESDAY, Sept. 7 (HealthDay News) ... expose children to the controversial chemical bisphenol A (BPA), a ... remains unclear whether or not it poses a long-term health ... saliva can cause the fillings and sealants to leach. This ...
... in primary care cut heart disease deaths and hospital ... published online in the Journal of Epidemiology and ... financial incentives to quality improvement has improved the overall ... far there has been little evidence to suggest that ...
Cached Medicine News:Health News:For migrant workers, community cooperation builds on individual strengths 2Health News:For migrant workers, community cooperation builds on individual strengths 3Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Mount Sinai researchers find new target to improve pain management 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 3Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 4Health News:Fillings, Sealants May Leach BPA Into Kids' Mouths 2Health News:Fillings, Sealants May Leach BPA Into Kids' Mouths 3Health News:Primary care financial incentives cut heart disease deaths and admissions 2
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: